US EditionAntengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
Antengene reported a 40% objective response rate for ATG-022 in Phase I/II trials and outlined multiple investigational new drug applications planned through 2027.
- At the 44th Annual J.P. Morgan Healthcare Conference, Antengene presented clinical data for ATG-022 and progress on next-gen ADCs and TCEs, sharing updates from ongoing studies.
- With a Dec. 25, 2025 cutoff, the ATG-022 dataset shows results from the Phase I/II CLINCH study and Phase Ib/II CLINCH-2 study in Mainland of China and Australia.
- At 1.8 mg/kg the data show ATG-022 achieved ORR 46.7% and DCR 86.7% , with mPFS 6.97 months.
- Antengene says ATG-022's differentiated safety profile positions it as a potential best-in-class ADC and may allow combinations with checkpoint inhibitors and chemotherapy, while the company plans an IND submission for ATG-125 in Q1 2027 and highlighted AnTenGager TCE platform's design to reduce CRS and broaden applicability.
- Antengene's broader pipeline and approvals include 32 IND approvals, NDAs filed in 11 Asia Pacific markets, XPOVIO approved in multiple jurisdictions and insured in five markets, with planned INDs for ATG-106 and ATG-110 in the first half of 2027 and ATG-112 nominated in January 2026.
30 Articles
30 Articles
The Billings Gazette
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
SHANGHAI and HONG KONG, Jan. 15, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies…
Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
SHANGHAI and HONG KONG, Jan. 15, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference …
Coverage Details
Bias Distribution
- 82% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
